PMID- 38183564
OWN - NLM
STAT- Publisher
LR  - 20240106
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Linking)
DP  - 2024 Jan 6
TI  - Quantitative analysis of Tr1 lymphocytes in patients with type 2 diabetes 
      mellitus.
LID - 10.1007/s40618-023-02250-w [doi]
AB  - BACKGROUND: Type 2 diabetes mellitus (T2DM) is usually accompanied by a low-grade 
      inflammatory phenomenon, which participates in the pathogenesis of different 
      complications of this condition. The inflammatory response is under the 
      regulation of different mechanisms, including T regulatory (Treg) lymphocytes. 
      However, the possible role of type 1 T regulatory (Tr1) cells in T2DM has not 
      been explored so far. AIM: To carry out a quantitative analysis of Tr1 
      lymphocytes and other immune cell subsets in patients with T2DM and correlate 
      these results with clinical findings and treatments. MATERIALS AND METHODS: Sixty 
      patients with T2DM and twenty-three healthy controls were included in the study. 
      Biochemical and anthropometric variables were evaluated, and Tr1 lymphocytes 
      (CD4(+)CD49(+)LAG-3(+)IL-10(+)) and other cell subsets (Th17, Th22 and 
      Foxp3 + Treg cells) were analyzed in peripheral blood samples by multiparametric 
      flow cytometry. RESULTS: Significant increased levels of Tr1 cells were detected 
      in patients with severe and mild disease, compared to healthy controls. In 
      addition, CD4(+)IL-10(+) lymphocytes were also increased in patients with T2DM. 
      In contrast, similar levels of Foxp3(+) Treg cells, Th17 and Th22 lymphocytes 
      were observed in patients and controls. Likewise, no significant associations 
      were detected between Tr1 cell levels and different clinical and laboratory 
      parameters. However, those patients receiving glucagon-like peptide-1 receptor 
      agonists (GLP-1-RA) showed similar levels of Tr1 cells than healthy controls, and 
      significant lower numbers than untreated patients. CONCLUSION: We observed an 
      increase in Tr1 and CD4(+)IL10(+) lymphocyte levels in T2DM. Moreover, GLP1-RA 
      treatment was significantly associated with normalization of the Tr1 levels. This 
      highlights another potential immune dysfunction in patients with T2DM, which 
      could participate in the pathogenesis of this condition.
CI  - (c) 2024. The Author(s).
FAU - Knott-Torcal, C
AU  - Knott-Torcal C
AD  - Department of Endocrinology and Nutrition, Health Research Institute, Hospital 
      Universitario de La Princesa, Universidad Autonoma de Madrid, C/Diego de Leon 62, 
      28006, Madrid, Spain.
AD  - Faculty of Pharmacy, Universidad Complutense de Madrid, Av. Seneca, 2, 28040, 
      Madrid, Spain.
FAU - de la Blanca, N S
AU  - de la Blanca NS
AD  - Department of Endocrinology and Nutrition, Health Research Institute, Hospital 
      Universitario de La Princesa, Universidad Autonoma de Madrid, C/Diego de Leon 62, 
      28006, Madrid, Spain.
FAU - Serrano-Somavilla, A
AU  - Serrano-Somavilla A
AD  - Department of Endocrinology and Nutrition, Health Research Institute, Hospital 
      Universitario de La Princesa, Universidad Autonoma de Madrid, C/Diego de Leon 62, 
      28006, Madrid, Spain.
FAU - Hernandez, R M
AU  - Hernandez RM
AD  - Department of Endocrinology and Nutrition, Health Research Institute, Hospital 
      Universitario de La Princesa, Universidad Autonoma de Madrid, C/Diego de Leon 62, 
      28006, Madrid, Spain.
FAU - Sampedro-Nunez, M
AU  - Sampedro-Nunez M
AD  - Department of Endocrinology and Nutrition, Health Research Institute, Hospital 
      Universitario de La Princesa, Universidad Autonoma de Madrid, C/Diego de Leon 62, 
      28006, Madrid, Spain.
FAU - Ruiz-Rosso, B
AU  - Ruiz-Rosso B
AD  - Faculty of Pharmacy, Universidad Complutense de Madrid, Av. Seneca, 2, 28040, 
      Madrid, Spain.
FAU - Jimenez-Blanco, S
AU  - Jimenez-Blanco S
AD  - Department of Endocrinology and Nutrition, Health Research Institute, Hospital 
      Universitario de La Princesa, Universidad Autonoma de Madrid, C/Diego de Leon 62, 
      28006, Madrid, Spain.
FAU - Gonzalez-Amaro, R
AU  - Gonzalez-Amaro R
AD  - Research Center of Health Sciences and Biomedicine (CICSaB), Universidad Autonoma 
      de San Luis Potosi, SLP, Mexico.
FAU - Gonzalez-Baranda, L
AU  - Gonzalez-Baranda L
AD  - Research Center of Health Sciences and Biomedicine (CICSaB), Universidad Autonoma 
      de San Luis Potosi, SLP, Mexico.
FAU - Garcimartin, A
AU  - Garcimartin A
AD  - Faculty of Pharmacy, Universidad Complutense de Madrid, Av. Seneca, 2, 28040, 
      Madrid, Spain. garcimartin.a@gmail.com.
FAU - Marazuela, M
AU  - Marazuela M
AUID- ORCID: 0000-0001-5829-1582
AD  - Department of Endocrinology and Nutrition, Health Research Institute, Hospital 
      Universitario de La Princesa, Universidad Autonoma de Madrid, C/Diego de Leon 62, 
      28006, Madrid, Spain. monica.marazuela@uam.es.
LA  - eng
GR  - PI19-00584/Instituto de Salud Carlos III/
GR  - PI22/01404/Instituto de Salud Carlos III/
GR  - PMP22/00021/Instituto de Salud Carlos III/
GR  - P2022/BMD7379/Comunidad de Madrid/
PT  - Journal Article
DEP - 20240106
PL  - Italy
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
SB  - IM
OTO - NOTNLM
OT  - T regulatory cells
OT  - T2DM
OT  - Tr1 lymphocytes
EDAT- 2024/01/07 06:42
MHDA- 2024/01/07 06:42
CRDT- 2024/01/06 11:11
PHST- 2023/08/04 00:00 [received]
PHST- 2023/11/13 00:00 [accepted]
PHST- 2024/01/07 06:42 [medline]
PHST- 2024/01/07 06:42 [pubmed]
PHST- 2024/01/06 11:11 [entrez]
AID - 10.1007/s40618-023-02250-w [pii]
AID - 10.1007/s40618-023-02250-w [doi]
PST - aheadofprint
SO  - J Endocrinol Invest. 2024 Jan 6. doi: 10.1007/s40618-023-02250-w.